Current Neuro-Oncology

Volume 27 Number 22
10 August 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 22, 10 August

Bubeníková A, Haratek K, Táborská J, Trková K, Sumerauer D, Kynčl M, Krsková L, Koblížek M, Zámečník J, Libý P, Tichý M, Bradáč O, Zápotocký M, Beneš V 3rd.
Long-term prognosis and treatment outcomes in infantile and neonatal brain tumors.
Childs Nerv Syst. 2025 Aug 1;41(1):251. doi: 10.1007/s00381-025-06881-7. PMID: 40748501. Observational study˰ ˍ AI Overv

Sun TC, Yu CF, Wu SY, Cheng WC, Chiang CS, Chen FH.
Microglia limit brain tumor development by restricting tumor cell proliferation and inducing T-cell immunity.
Mol Oncol. 2025 Aug 1. doi: 10.1002/1878-0261.70102. PMID: 40747560. Lab investigation. ˍ AI Overv

Choi MJ, So EY, Akosman B, Lee YE, Raufi AG, Bertone P, Reginato AM, Chen CC, Lawler SE, Wong ET, Liang OD.
Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager.
bioRxiv [Preprint]. 2025 Aug 2:2025.07.30.667708. doi: 10.1101/2025.07.30.667708. PMID: 40766453. Lab investigation. ˍ AI Overv

Ferles A, Majewska P, Holden Helland R, Kommers I, Pedersen A, Tranfa M, Ardon H, Bello L, Berger MS, Dunås T, Nibali MC, Furtner J, Hervey-Jumper SL, Idema AJS, Kiesel B, Tewarie RN, Mandonnet E, Robe PA, Rossi M, Sciortino T, Aalders T, Wagemakers M, Widhalm G, Zwinderman AH, Sagberg LM, Jakola AS, Thurin E, Reinertsen I, Bouget D, Solheim O, Eijgelaar RS, de Witt Hamer PC, Barkhof F.
Estimating overall survival of glioblastoma patients using clinical variables, tumor size, and location.
Neurooncol Adv. 2025 Aug 3;7(1):vdaf154. doi: 10.1093/noajnl/vdaf154. PMID: 40842642. Observational study. ˍ

Bosio A, Cerretti G, Padovan M, Del Bianco P, Polano M, Mandruzzato S, Indraccolo S, Manara R, Librizzi G, Caccese M, Corrà M, Maccari M, Lonardi S, De Salvo GL, Lombardi G.
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).
Trials. 2025 Aug 4;26(1):268. doi: 10.1186/s13063-025-08997-2. PMID: 40759981. Interventional study protocol. ˍ AI Overv

Pabst KM, Weber MM, Laschinsky C, Sandach P, Bartel T, Küper AT, Kessler L, Trajkovic-Arsic M, Eckstein M, Gilman E, Nader M, Barbato F, Podleska LE, Hadaschik BA, Hamacher R, Kersting D, von Ostau N, von Tresckow B, Kaelberlah HP, Kesch C, Kuemmel S, Reinacher-Schick A, Schuler M, Siveke JT, Grünwald V, Herrmann K, Fendler WP.
[⁶⁸Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial.
Lancet Oncol. 2025 Aug 4:S1470-2045(25)00299-2. doi: 10.1016/S1470-2045(25)00299-2. PMID: 40774265. Interventional study. ˍ

Liu Y, Ma L, Fu X, Zhang Y, Zheng J, Chen Z.
Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database.
Front Pharmacol. 2025 Aug 6;16:1578406. doi: 10.3389/fphar.2025.1578406. PMID: 40843381. Observational study. ˍ

Albert NL, Tabouret E, Le Rhun E, Sahm F, Furtner J, Tonn JC, Alfano C, Silva JP, Govaerts AS, Gorlia T, Mirante O, Minniti G, Weller M, Preusser M; European Organisation for Research and Treatment of Cancer Brain Tumor Group.
[¹⁷⁷Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial.
J Nucl Med. 2025 Aug 7:jnumed.125.269633. doi: 10.2967/jnumed.125.269633. PMID: 40774695. Interventional study protocol. ˍ

Tan PK, Martins TJ, Becker PS, Wechsler-Reya RJ, Crawford JR.
Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.
Front Oncol. 2025 Aug 7;15:1606575. doi: 10.3389/fonc.2025.1606575. PMID: 40852486. Case report. ˍ

Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP.
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
J Clin Oncol. 2025 Aug 8:JCO2500618. doi: 10.1200/JCO-25-00618. PMID: 40779733. Interventional study. ˍ

Oki S, Yamaguchi S, Ishi Y, Motegi H, Gekka M, Tanei ZI, Kanno-Okada H, Takakuwa E, Tanaka S, Mori T, Nishioka K, Aoyama H, Tanaka S, Fujimura M.
Recurrence patterns and clinical outcomes in adult cerebellar glioblastoma.
Acta Neurochir (Wien). 2025 Aug 8;167(1):217. doi: 10.1007/s00701-025-06633-1. PMID: 40779131. Observational study. ˍ AI Overv

Genc O, Tabakci ON, Uysal E, Şahin SA, Tanık CT.
The Diagnostic Value of Susceptibility-Weighted Imaging in Preoperative Grading of Glial Tumors.
Cureus. 2025 Aug 10;17(8):e89757. doi: 10.7759/cureus.89757. PMID: 40791217. Observational study. ˍ AI Overv

Scheu K, Vandieken E, Hense K, Rosengarth K, Haedenkamp T, Lenglinger M, Bumes E, Linker R, Proescholdt M, Schmidt NO, Riemenschneider MJ, Wendl C, Wiesinger I, Hau P.
MRI-defined patterns of infiltration and outcome in patients with glioblastoma.
Neurooncol Adv. 2025 Jul 10;7(1):vdaf114. doi: 10.1093/noajnl/vdaf114. PMID: 40842643. Observational study. ˍ AI Overv